Cerus (NASDAQ:CERS) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Cerus (NASDAQ:CERS) announced its earnings results on Thursday. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Briefing.com reports. Cerus had a negative return on equity of 74.31% and a negative net margin of 90.68%. The business had revenue of $18.20 million for the quarter, compared to analyst estimates of $17.55 million. During the same quarter last year, the company posted ($0.10) EPS. Cerus’s quarterly revenue was up 18.2% on a year-over-year basis. Cerus updated its FY 2019 guidance to EPS.

Shares of CERS traded down $0.51 during mid-day trading on Friday, hitting $5.34. 1,647,833 shares of the company’s stock were exchanged, compared to its average volume of 792,261. Cerus has a fifty-two week low of $4.49 and a fifty-two week high of $8.05. The stock has a market cap of $806.34 million, a price-to-earnings ratio of -12.14 and a beta of 1.60. The company has a 50 day simple moving average of $5.35. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.83 and a quick ratio of 2.50.

Several equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research downgraded shares of Cerus from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Finally, ValuEngine upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.50.

In other Cerus news, insider William Mariner Greenman bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was acquired at an average price of $4.60 per share, for a total transaction of $46,000.00. Following the completion of the purchase, the insider now owns 638,485 shares of the company’s stock, valued at $2,937,031. The acquisition was disclosed in a filing with the SEC, which is available through this link. 7.26% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in CERS. Aperio Group LLC acquired a new stake in shares of Cerus during the second quarter worth about $27,000. Virtu Financial LLC raised its holdings in Cerus by 16.6% during the first quarter. Virtu Financial LLC now owns 12,639 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 1,798 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in Cerus by 141.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 19,824 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 11,624 shares in the last quarter. Amalgamated Bank purchased a new position in Cerus during the fourth quarter worth about $99,000. Finally, SG Americas Securities LLC raised its holdings in Cerus by 23.9% during the first quarter. SG Americas Securities LLC now owns 16,317 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 3,151 shares in the last quarter. Institutional investors and hedge funds own 66.21% of the company’s stock.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Read More: What are the benefits of investing in REITs?

Earnings History for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.